help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2009-0017
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banu, S. K.
Right arrow Articles by Arosh, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banu, S. K.
Right arrow Articles by Arosh, J. A.
Molecular Endocrinology 23 (8): 1291-1305
Copyright © 2009 by The Endocrine Society

Selective Inhibition of Prostaglandin E2 Receptors EP2 and EP4 Induces Apoptosis of Human Endometriotic Cells through Suppression of ERK1/2, AKT, NF{kappa}B, and β-Catenin Pathways and Activation of Intrinsic Apoptotic Mechanisms

Sakhila K. Banu1, JeHoon Lee1, V. O. Speights, Jr., Anna Starzinski-Powitz and Joe A. Arosh

Reproductive Endocrinology and Cell Signaling Laboratory (S.K.B., J.L., J.A.A.), Department of Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas 77843; Division of Anatomic Pathology (V.O.S.), Department of Pathology, Scott and White Memorial Hospital, Texas A&M University Health Science Center, Temple, Texas 76508; and Molekulare Zellbiologie und Humangenetik (A.S.-P.), Institut für Zellbiologie und Neurowissenschaft, Johann Wolfgang Goethe-Universität, 60323 Frankfurt am Main, Germany

Address all correspondence and requests for reprints to: Joe A. Arosh, Ph.D., Department of Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Mail Stop TAMU 4458, Texas A&M University, College Station, Texas 77843. E-mail: jarosh{at}cvm.tamu.edu.

Endometriosis is a benign chronic gynecological disease of reproductive-age women characterized by the presence of functional endometrial tissues outside the uterine cavity. It is an estrogen-dependent disease. Current treatment modalities to inhibit biosynthesis and actions of estrogen compromise menstruation, pregnancy, and the reproductive health of women and fail to prevent reoccurrence of disease. There is a critical need to identify new specific signaling modules for non-estrogen-targeted therapies for endometriosis. In our previous study, we reported that selective inhibition of cyclooxygenase-2 prevented survival, migration, and invasion of human endometriotic epithelial and stromal cells, which was due to decreased prostaglandin E2 (PGE2) production. In this study, we determined mechanisms through which PGE2 promoted survival of human endometriotic cells. Results of the present study indicate that 1) PGE2 promotes survival of human endometriotic cells through EP2 and EP4 receptors by activating ERK1/2, AKT, nuclear factor-{kappa}B, and β-catenin signaling pathways; 2) selective inhibition of EP2 and EP4 suppresses these cell survival pathways and augments interactions between proapoptotic proteins (Bax and Bad) and antiapoptotic proteins (Bcl-2/Bcl-XL), facilitates the release of cytochrome c, and thus activates caspase-3/poly (ADP-ribose) polymerase-mediated intrinsic apoptotic pathways; and 3) these PGE2 signaling components are more abundantly expressed in ectopic endometriosis tissues compared with eutopic endometrial tissues during the menstrual cycle in women. These novel findings may provide an important molecular framework for further evaluation of selective inhibition of EP2 and EP4 as potential therapy, including nonestrogen target, to expand the spectrum of currently available treatment options for endometriosis in women.




This article has been cited by other articles:


Home page
EndocrinologyHome page
L. Aghajanova, J. A. Horcajadas, J. L. Weeks, F. J. Esteban, C. N. Nezhat, M. Conti, and L. C. Giudice
The Protein Kinase A Pathway-Regulated Transcriptome of Endometrial Stromal Fibroblasts Reveals Compromised Differentiation and Persistent Proliferative Potential in Endometriosis
Endocrinology, March 1, 2010; 151(3): 1341 - 1355.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society